Content about Lundbeck

December 12, 2012
FDA accepts application for Takeda, Lundbeck antidepressant

The Food and Drug Administration has accepted a regulatory approval application from Takeda and Lundbeck for an experimental drug to treat depression, the companies said Wednesday.

DEERFIELD, Ill. — The Food and Drug Administration has accepted a regulatory approval application from Takeda and Lundbeck for an experimental drug to treat depression, the companies said Wednesday.

The FDA will review the companies' application for vortioxetine for the treatment of major depressive disorder in adults. The agency expects to finish reviewing the application by Oct. 2, 2013.

October 2, 2012
Takeda, Lundbeck seek FDA nod for depression drug

Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.

OSAKA, Japan — Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.

Japan-based Takeda and Denmark-based Lundbeck announced the submission of a new drug application for Lu AA21004 (vortioxetine) for major depressive disorder.

September 14, 2012
Lundbeck adds Omnicare to limited distribution network for Huntington's drug

The specialty pharmacy operated by Omnicare Specialty Care Group has been added to the limited distribution network for a drug used to treat a hereditary degenerative disorder.

ORLANDO, Fla. — The specialty pharmacy operated by Omnicare Specialty Care Group has been added to the limited distribution network for a drug used to treat a hereditary degenerative disorder.

Omnicare said Friday that Lundbeck had added Advanced Care Scripts to its network for Xenaziner (tetrabenazine). The drug is used to treat involuntary movements known as chorea associated with Huntington's disease. Chroea affects about 90% of people with Huntington's and is considered a hallmark of the disease, according to studies.

December 22, 2010
PhRMA expands board of directors

The Pharmaceutical Research and Manufacturers of America has added four new members to its board.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America has added four new members to its board.

Joining PhRMA are Ian Read, Pfizer's president and CEO; Jerzy Gruhn, Novo Nordisk president; Mark Iwicki, Sunovion Pharmaceuticals president and COO; and Staffan Schuberg, Lundbeck president.